Product image of Ngenla (Somatrogon) supplied by GNH India

Ngenla

Active Ingredient:
Somatrogon
Origin:
EU

Ngenla (Somatrogon)

Somatrogon, the active ingredient in Ngenla, is a growth hormone analog presented as a subcutaneous injection for subcutaneous use. It treats growth hormone deficiency in children and is indicated for Turner syndrome and Prader‑Willi syndrome.

GNH India supplies Ngenla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Pfizer Europe Ma Eeig

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ngenla is used in pediatric and genetic conditions that involve impaired growth hormone pathways.

  • Growth hormone deficiency in children: restores normal growth velocity and supports height development.
  • Turner syndrome: promotes linear growth and improves final adult height.
  • Prader‑Willi syndrome: enhances growth parameters and may improve body composition.

How It Works

  • Somatrogon is a recombinant fusion protein that mimics endogenous growth hormone. After subcutaneous injection it binds to growth hormone receptors on target cells, activating the JAK2‑STAT5 signaling cascade. This stimulation increases hepatic production of insulin‑like growth factor‑1 (IGF‑1) and triggers downstream anabolic processes that promote linear growth, protein synthesis, and metabolic regulation. The prolonged half‑life of somatrogon allows once‑weekly dosing, maintaining more stable IGF‑1 levels compared with daily recombinant human growth hormone.

Side Effects

Somatrogon may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects

  • Injection site pain: mild discomfort or redness at the injection site.
  • Headache: transient headache occurring after dosing.
  • Nausea: occasional feeling of nausea without vomiting.
  • Transient edema: mild swelling of hands or feet.

Serious or Rare Side Effects

  • Intracranial hypertension: signs include severe headache, visual changes, or vomiting.
  • Allergic reactions: rash, urticaria, or anaphylaxis requiring immediate medical attention.
  • Glucose intolerance: elevated blood glucose or new‑onset diabetes mellitus.
  • Scoliosis progression: accelerated curvature in patients with pre‑existing spinal curvature.

Precautions & Warnings

When prescribing somatrogon, clinicians should observe several precautionary measures to ensure safe use.

  • Assess baseline IGF‑1 and growth parameters: establish reference values before initiating therapy.
  • Monitor for signs of intracranial hypertension: evaluate headache, visual acuity, and papilledema regularly.
  • Screen for glucose metabolism disorders: check fasting glucose or HbA1c periodically.
  • Evaluate thyroid function: hypothyroidism can affect growth response, adjust levothyroxine if needed.
  • Avoid use in patients with active malignancy: growth hormone may stimulate tumor growth.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Somatrogon can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Concurrent use of high‑dose glucocorticoids: may blunt IGF‑1 response and reduce growth effect.
  • Insulin or oral hypoglycemics: somatrogon can increase insulin resistance, requiring dose adjustment.
  • Medications that increase intracranial pressure (e.g., tetracyclines): may exacerbate risk of hypertension.

Moderate Interactions (Monitor Closely)

  • Thyroid hormone replacement: somatrogon may increase thyroid hormone requirements.
  • Estrogen therapy: can augment IGF‑1 levels, necessitating monitoring.
  • Cytochrome P450 inducers (e.g., rifampin): may modestly reduce somatrogon exposure.

Frequently Asked Questions

Ngenla is prescribed for children with growth hormone deficiency, as well as for individuals with Turner syndrome or Prader‑Willi syndrome. In each condition the drug aims to replace deficient endogenous growth hormone, thereby supporting normal linear growth and improving overall growth outcomes.

Somatrogon is a recombinant growth hormone analog that binds to growth hormone receptors on target cells. This binding activates intracellular JAK2‑STAT5 signaling, leading to increased production of insulin‑like growth factor‑1 (IGF‑1) by the liver and stimulating the anabolic processes that drive bone growth, protein synthesis, and metabolic regulation.

The dose of Ngenla is individualized. A qualified prescriber determines the appropriate amount, frequency and duration based on the patient’s age, weight, IGF‑1 levels, and specific indication. Dosing regimens are not standardized and should be followed exactly as written by the treating physician.

Safety data for somatrogon in pregnancy and lactation are limited. It is generally recommended to avoid use during pregnancy unless the potential benefit justifies the potential risk. Women who are breastfeeding should also discuss the need for therapy with their healthcare provider, as the drug may be present in breast milk.

To request Ngenla, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

Ngenla (somatrogon) has a longer half‑life than daily recombinant human growth hormone, allowing once‑weekly subcutaneous injections instead of daily dosing. This can improve adherence while providing comparable IGF‑1 exposure. Clinical studies suggest similar efficacy in height velocity, though individual response may vary.

Ngenla must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and do not freeze or shake the product. If temporary temperature excursions occur, consult the product’s stability guidelines before use.

Ngenla is given by subcutaneous injection, typically into the thigh, abdomen or upper arm. The injection is performed by a trained healthcare professional or a caregiver after proper instruction. The recommended frequency is once per week, but the exact schedule is set by the prescribing clinician.

Serious adverse events include intracranial hypertension (characterized by severe headache, visual changes, or vomiting), severe allergic reactions such as anaphylaxis, and new‑onset or worsening glucose intolerance that may lead to diabetes. Patients should be monitored regularly for these conditions and instructed to seek immediate medical attention if symptoms arise.

Ngenla is contraindicated in individuals with known hypersensitivity to somatrogon or any excipients, and it should be avoided in patients with active malignancies because growth hormone can potentially stimulate tumor growth. Caution is also advised for patients with uncontrolled diabetes, severe scoliosis, or untreated intracranial hypertension.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Somatrogon

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT